Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
| CAPS Rating |
|
|---|---|
| Open | $2.00 |
| Previous Close | $2.02 |
| Daily Range | $1.91 - $2.00 |
| 52-Week Range | $1.21 - $2.62 |
| Market Cap | $283.17M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 2,308,842 |
| Average Daily Volume | 0 |
ARNA
VS S&P 500 (SPY)
How do you think ARNA will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ARNA Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ARNA News and Commentary
- The Skinny on Upcoming Obesity FDA Meetings – The Motley Fool
- Amgen, Vivus, Chelsea Therapeutics Prep for Key Catalysts in February – Minyanville
- The Simple Strategy That Beat the Market – The Motley Fool
- Zacks #1 Rank Additions for Thursday - Tale of the Tape – NASDAQ
- 6 Key Drivers for Biotechnology's 2012 Outlook – Minyanville
- Zacks #1 Rank Additions for Monday - Tale of the Tape – NASDAQ
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape – NASDAQ
- Diet Pill Scorecard: Vivus, Arena, Orexigen Still Chasing Market Approvals – Minyanville
- Has Arena Pharmaceuticals Become the Perfect Stock? – The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape – NASDAQ
- Arena: FDA Accepts Resubmitted Application For Weight-Loss Drug Lorcaserin – SmartMoney
- Don't Believe This Company's Warning – The Motley Fool
- Arena Pharma Files Response to CRL - Analyst Blog – NASDAQ
- This Biotech's Obese To-Do List Is Done – The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- 3 More Stock-Moving Binary Events to Watch in 2012 – The Motley Fool
- Working Through the Obese To-Do List in 2011 – The Motley Fool
- You've Got 4 Days Left to Do This – The Motley Fool
- VIVUS' Obese Pink Elephant – The Motley Fool
RSS Headlines
Fool UK
